Efficacy of a slow‐release formulation of lanreotide (Autogel<sup>®</sup> 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study

Ronchi, Cristina L.; Boschetti, Mara; Uberti, Ettore C. degli; Mariotti, Stefano; Grottoli, Silvia; Loli, Paola; Lombardi, Gaetano; Tamburrano, G.; Arvigo, Marica; Angeletti, G; Boscani, P. F.; Beck‐Peccoz, Paolo; Arosio, Maura

doi:10.1111/j.1365-2265.2007.02917.x

Cited by 67 publications

(54 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In fact, lanreotide Autogel is a new formulation of lanreotide with comparable biochemical efficacy to lanreotide SR and potential advantages for the compliance of the patients related to the type (i.e deep subcutaneous) and modality of administration [52][53][54][55][56][57][58][59][60][61]. In fact, it does not require any reconstitution procedures which, if incomplete, may result in needle blockage by microparticles.…”

Section: Discussionmentioning

confidence: 94%

Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review

Mazziotti,

Giustina

2009

Pituitary

View full text Add to dashboard Cite

Long-acting somatostatin analogs (SSA) are widely used for the treatment of acromegaly achieving biochemical control of the disease in 50-75% of the patients. One of the goals of the treatment of acromegaly is the control of tumor growth, especially in patients in whom SSAs are used as first-line therapy. Over the recent years, there has been growing evidence that SSAs are able to induce tumor shrinkage in patients with acromegaly. However, most of the data are from patients under treatment with octreotide, either subcutaneously or intramuscularly with long-acting formulation, whereas the data on lanreotide SR or Autogel are very few. Indeed, octreotide and lanreotide, i.e. the two commercially available SSAs, show slight differences in pharmacokinetics and patterns of receptor affinities with potentially different therapeutic effects. We aimed to perform a systematic review of literature data concerning the shrinkage effects of long-acting lanreotide in patients with acromegaly. The analysis was focused on the following issues: differences in shrinkage effects between primary and secondary medical treatment, predictive value of baseline tumor volume and correlation between biochemical control and shrinkage effects. The peer-reviewed medical literature was searched to identify clinical trials studying the effects of lanreotide SR or Autogel on adenoma size in acromegaly. To be included in this analysis, studies had one of the following designs: randomized controlled trial; prospective, nonrandomized trial; retrospective study. Twenty-two studies were found to be eligible for the final analysis, in which tumor size was measured as an end-point for lanreotide treatment. Overall a total of 32.8% of patients experienced a variable degree (from 10 to 77%) of tumor shrinkage during lanreotide SR or Autogel treatment. The analysis showed that tumor shrinkage was more frequent in naïve patients as compared with those previously treated by radiotherapy, surgery or drugs other than lanreotide. The data on the correlation between tumor shrinkage and baseline tumor size were discordant, but when baseline tumor size was specified, more than 80% of patients undergoing shrinkage under lanreotide Autogel had macroadenomas. Finally, with lanreotide Autogel there was no evident correlation between biochemical response and tumor shrinkage. Our systematic review of the literature shows that lanreotide particularly when used as first-line therapy is able to quite frequently induce tumor shrinkage in patients with acromegaly. This finding suggests that this drug may have a role in the primary treatment of acromegaly.

show abstract

Section: Discussionmentioning

confidence: 94%

Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review

Mazziotti,

Giustina

2009

Pituitary

View full text Add to dashboard Cite

show abstract

“…Depot SRLs have been consistently shown to reduce hormonal hypersecretion in most patients with acromegaly and to normalize IGF-I levels in many of them [11,[21][22][23][24]. These preparations include lanreotide PR 30 mg, injected every 7-14 days, and lanreotide Autogel and octreotide LAR, which have extended action duration of 28 days.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of long-term lanreotide treatment in patients with acromegaly

et al. 2009

View full text Add to dashboard Cite

We investigated the effectiveness of lanreotide for the treatment of active acromegaly in a retrospectively multicenter case series including 53 patients (24 male, 29 female; mean age at diagnosis, 49.5 +/- 13.9 years) with acromegaly treated with lanreotide in nine different centers. Mean tumor diameter was 20 +/- 13 mm; mean basal levels of growth hormone (GH) and insulin-like growth factor I (IGF-I) were 21.3 +/- 26.3 and 579 +/- 177 mug/l, respectively. The primary mode of treatment was surgery in 70% of patients. Twenty-nine patients received only lanreotide (Prolonged Release, Autogel), whereas 24 subjects were also treated with octreotide at another treatment stage. Primary therapy with lanreotide was administered in five patients. Maximal monthly dose of lanreotide Autogel (n = 44) was 60 mg in 45%, 90 mg in 26%, 120 mg in 21% and 180 mg in 8%. During 36 months of lanreotide treatment, mean IGF-I levels decreased from 443 +/- 238 to 276 +/- 147 mug/l (P < 0.001), and mean GH levels, from 5.2 +/- 6.4 to 3.2 +/- 3.0 mug/l (P < 0.001). IGF-I levels normalized in 51% of patients and decreased by >50% towards normal in 32%; the normalization rate was higher in women (65%) than men (33%, P = 0.04). Safe random GH levels (

show abstract

“…Эффекты лечения Соматулином ® Аутожель ® изу -чались как в краткосрочных (до 1 года) [4,7,11,12], так и длительных (до 3 лет) исследованиях в сравнении с Соматулином продленного действия и Сандостатином ЛАР, в которых он показал равнозначную эффективность с препаратами сравнения [4,24,26], что в целом также на-блюдалось на примере представляемой нами пациентки.…”

Section: Discussionunclassified

“…Назначение Соматулина ® Аутожель ® 120 мг с интер-валом 6 недель основывалось на данных исследования Ronchi C.L. и соавт., показавшего эффективность при-менения этой дозировки препарата у пациентов с уве-личенным интервалом от 6 до 8 недель [24].…”

Section: Discussionunclassified

See 1 more Smart Citation

Autozhel' v kontrole biokhimicheskikh markerovaktivnosti akromegalii: predstavlenieklinicheskogo sluchaya

Dzeranova¹,

Giniyatullina²,

Pigarova³

et al. 2010

Obes. metabol.

View full text Add to dashboard Cite

Acromegaly is a severe neuroendocrine disease that develops when the pituitary gland produces excess growth hormone (GH). Acromegaly is not only a cosmetic problem. Hypersecretion of GH leads to variety complications, decreased quality of life, shortening the expected lifespan due to development of severe cardiovascular complications. Timely diagnosis and adequate treatment can reduce mortality by 2-5 times and medical therapy deservedly plays an important role in treatment of patients with acromegaly when radical surgical treatment cannot be performed. We present a first Russian experience of acromegaly patient treatment with new preparation - Somatulin Autogel, with analysis of its favorable effects on clinical and metabolic manifestations of the disease.

show abstract

Efficacy of a slow‐release formulation of lanreotide (Autogel^® 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study

Abstract: Lanreotide Autogel 120 mg is an effective and well-tolerated therapy for acromegaly. In approximately half of patients ATG120 may be administered every 6-8 weeks, instead of every 4 weeks, without lost of efficacy.

Cited by 67 publications

References 41 publications

Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review

Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review

Efficacy of long-term lanreotide treatment in patients with acromegaly

Autozhel' v kontrole biokhimicheskikh markerovaktivnosti akromegalii: predstavlenieklinicheskogo sluchaya

Contact Info

Product

Resources

About

Efficacy of a slow‐release formulation of lanreotide (Autogel® 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study

Abstract: Lanreotide Autogel 120 mg is an effective and well-tolerated therapy for acromegaly. In approximately half of patients ATG120 may be administered every 6-8 weeks, instead of every 4 weeks, without lost of efficacy.

Cited by 67 publications

References 41 publications

Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review

Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review

Efficacy of long-term lanreotide treatment in patients with acromegaly

Autozhel' v kontrole biokhimicheskikh markerovaktivnosti akromegalii: predstavlenieklinicheskogo sluchaya

Contact Info

Product

Resources

About

Efficacy of a slow‐release formulation of lanreotide (Autogel^® 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study